on Cherry SE (isin : DE000A3CRRN9)
Cherry SE: SmartLink Product Approval is Imminent
Munich, 17 September 2024 - Cherry SE has announced the imminent product approval of CHERRY SmartLink. This product is currently in the final testing phase by external partners and the approval body to ensure product safety.
The market for CardLink solutions is competitive, with various factors influencing the launch such as technical implementation, pricing, and pharmacies' purchase commitments. CHERRY's business model charges only for actual transactions, aiming to create long-term benefits for all stakeholders.
Cherry SE CEO Oliver Kaltner highlighted the importance of expanding business models with recurring revenue. He emphasized that CHERRY SmartLink embodies the digitalization of healthcare, offering a patient-oriented, data-secure digital solution with robust safety and quality standards.
CHERRY SmartLink is a SaaS solution allowing NFC-enabled smartphones to function as eHealth card terminals. This new offering facilitates secure e-prescription redemption via CardLink, integrating an approved interface into apps for seamless use.
R. P.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Cherry SE news